News

STAT4mOpinion
The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear
The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...
Seeking Alpha25m
Sarepta shares cut to $0 at H.C. Wainwright
H.C. Wainwright has taken the unusual step of setting a $0 price target for troubled biotech Sarepta Therapeutics (NASDAQ:SRPT). The firm, which rates the stock a sell, previously had a $10 price ...